ITEM METADATA RECORD
Title: Endocrine determinants of incident sarcopenia in middle-aged and elderly European men
Authors: Gielen, Evelien ×
O'Neill, T.W.
Pye, S.R.
Adams, J.E.
Laurent, Michaƫl
Claessens, Frank
Ward, K.A.
Boonen, Steven
Bouillon, Roger
Vanderschueren, Dirk
Verschueren, Sabine #
Issue Date: 2015
Publisher: Wiley
Series Title: Journal of Cachexia, Sarcopenia and Muscle vol:6 issue:3 pages:242-252
Abstract: Background: In men, the long-term consequences of low serum levels of sex steroids, vitamin D metabolites, and insulin-like growth factor 1 (IGF-1) on the evolution of muscle mass, muscle strength, or physical performance are unclear. Moreover, there are no data about the relationship between these hormones and incident sarcopenia defined as low muscle mass and function. The aim of this study was to determine whether the baseline levels of sex hormones, vitamin D metabolites, and IGF-1 predict changes in muscle mass, muscle strength, physical performance, and incident sarcopenia. Methods: In 518 men aged 40-79years, recruited for participation in the European Male Ageing Study, total, free, and bioavailable testosterone (T), oestradiol (E), sex hormone-binding globulin, IGF-1, 25-hydroxyvitamin D (25OHD), 1,25-dihydroxyvitamin D (1,25(OH)2D), and parathyroid hormone were assessed at baseline. Appendicular lean mass (aLM), gait speed, and grip strength were measured at baseline and after a mean follow-up of 4.3years. Sarcopenia was defined by the definition of Baumgartner (relative aLM ≤7.26kg/m2), the International Working Group on Sarcopenia (IWGS), and the European Working Group on Sarcopenia in Older People (EWGSOP). Results: aLM significantly decreased from age 50years, while gait speed and grip strength significantly decreased from age 70years. The incidence of sarcopenia by the definitions of Baumgartner, IWGS, and EWGSOP was 8.1%, 3.0%, and 1.6%, respectively. After adjustment for age, centre, body mass index, smoking, and number of comorbidities at baseline, baseline levels of T and vitamin D metabolites were not associated with change in aLM, gait speed, and/or grip strength, while a high baseline level of total E2 was associated with a greater decrease in aLM. In men aged ≥70years, low IGF-1 was associated with a greater decrease in gait speed. Baseline endocrine variables were not independently associated with an increased risk of incident sarcopenia by any definition. Conclusions: Low levels of T and 25OHD do not predict loss of muscle mass, gait speed, or grip strength in middle-aged and elderly community-dwelling European men. Low IGF-1 predicts change in gait speed in men aged ≥70years. © 2015 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders.
ISSN: 2190-5991
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Research Group for Musculoskeletal Rehabilitation
Gerontology and Geriatrics
Laboratory of Molecular Endocrinology
Clinical and Experimental Endocrinology
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Endocrine determinants of incident sarcopenia in middle-aged and elderly European men.pdf Accepted 4344KbAdobe PDFView/Open
Gielen_et_al-2015-Journal_of_Cachexia,_Sarcopenia_and_Muscle.pdf Published 216KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members

 




All items in Lirias are protected by copyright, with all rights reserved.

© Web of science